知Yizhi Daily
← Back to this edition

AI

Isomorphic Labs closes $5 billion Series C funding to advance AI drugs into clinical trials

Edition 2026-11-18 · 08:00 Beijing time

Isomorphic Labs, an AI drug discovery company spun out of DeepMind, announced the completion of $5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital. The company plans to use the funds to continue developing its drug design engine, expand into more disease areas, and advance candidate drugs into clinical trials; its oncology and immunology programs have already produced positive preclinical results.

Founded in 2021, Isomorphic Labs builds on the protein structure prediction achievements of DeepMind’s AlphaFold. The company has built a drug design engine composed of multiple simulation AI models, used to explore chemical space and assist in designing drugs.

In this funding round, Andreessen Horowitz participated as a new investor, while existing shareholders including GV, Capita G, Thrive Capital, MGX, Temasek, and the UK sovereign AI fund also continued investing. The company did not disclose its latest valuation; Bloomberg previously reported that it was seeking funding at a valuation of approximately $50 billion.

The company said its related programs have produced positive preclinical results in oncology and immunology, and it has formed partnerships with pharmaceutical companies including Eli Lilly, Novartis, and Johnson & Johnson. The company had only just completed a $2.1 billion Series B round in May.

This funding round is also the first since founder and CEO Demis Hassabis left his role as head of DeepMind, moved into the chairman role, and began focusing on drug discovery. Hassabis and John Jumper previously won the Nobel Prize in Chemistry for work related to AlphaFold.

Original sources

TechCrunch ↗
Back to this editionOpen interactive reader